New York Life Investment Management LLC Has $20.47 Million Stock Holdings in Boston Scientific Corporation $BSX

New York Life Investment Management LLC grew its stake in Boston Scientific Corporation (NYSE:BSX) by 6.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 214,666 shares of the medical equipment provider’s stock after acquiring an additional 13,458 shares during the period. New York Life Investment Management LLC’s holdings in Boston Scientific were worth $20,468,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Claret Asset Management Corp boosted its holdings in shares of Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after acquiring an additional 103 shares during the last quarter. Kera Capital Partners Inc. grew its position in shares of Boston Scientific by 3.3% in the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 109 shares during the period. Outfitters Financial LLC increased its stake in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares during the last quarter. Finally, Fayez Sarofim & Co increased its stake in shares of Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after purchasing an additional 111 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.0%

Boston Scientific stock opened at $53.61 on Friday. The company’s 50-day moving average price is $63.79 and its two-hundred day moving average price is $82.00. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock has a market cap of $79.67 billion, a P/E ratio of 22.43, a P/E/G ratio of 0.97 and a beta of 0.62. Boston Scientific Corporation has a twelve month low of $52.75 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts expect that Boston Scientific Corporation will post 3.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Needham & Company LLC cut their target price on shares of Boston Scientific from $97.00 to $77.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Raymond James Financial reissued an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Stifel Nicolaus cut their price objective on Boston Scientific from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, April 21st. Citigroup reduced their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Mizuho dropped their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $93.91.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific is being highlighted for strong international growth, with APAC momentum, FARAPULSE adoption, and new approvals in Europe and China helping expand its global footprint. Here’s How Boston Scientific Is Expanding Its Global Growth
• Positive Sentiment: Jim Cramer said he would “hold” BSX, implying he sees the company as a stock investors may want to keep rather than sell, which can help sentiment. Jim Cramer on Boston Scientific: “I Think You Gotta Hold It”
• Positive Sentiment: Recent commentary continues to point to Boston Scientific’s cardiovascular franchise as a long-term growth driver, with products like FARAPULSE and WATCHMAN supporting demand. Should You Buy, Hold or Sell BSX Stock Amid Cardiovascular Boom?
• Neutral Sentiment: The company treated its first patient with Seismiq IVL in the ELEGANCE registry, a small but positive clinical/commercial update that adds to its product pipeline narrative. Boston Scientific treats first patient with Seismiq IVL in ELEGANCE registry
• Neutral Sentiment: Boston Scientific filed a shelf registration tied to an ESOP-related offering and approved governance changes, which may help align incentives but also adds dilution/watch-list considerations for investors. Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
• Negative Sentiment: Some reports say BSX has fallen amid concerns that its growth may not be durable, which likely weighed on sentiment. Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability
• Negative Sentiment: Insiders reportedly sold about $1.2 million of shares, which can signal caution and add to investor concern during a weak stretch for the stock. Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
• Negative Sentiment: MarketWatch noted that Boston Scientific underperformed peers, reinforcing the view that investor sentiment remains cautious despite the company’s long-term growth story. Boston Scientific Corp. stock underperforms Wednesday when compared to competitors

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.